» Articles » PMID: 33848886

Antibiotics in Treatment of COVID-19 Complications: a Review of Frequency, Indications, and Efficacy

Overview
Publisher Elsevier
Date 2021 Apr 13
PMID 33848886
Citations 78
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: To report available information in the literature regarding frequency, indications, types of antibiotic usage, duration, and their efficacy in Covid-19 infected patients.

Methods: The search was conducted on April 30 and May 7, 2020, using Ovid database and Google search. Patients' characteristics, clinical outcomes, as well as selected characteristics regarding antibiotic use (indication, class used, rates and types of bacterial secondary and co-infection, and duration of treatment) were analyzed.

Results: Nineteen clinical studies reporting data from 2834 patients were included. Mean rate of antibiotic use was 74.0 % of cases. Half the studies reported occurrence of a bacterial co-infection or complication (10 studies). Amongst the latter, at least 17.6 % of patients who received antibiotics had secondary infections. Pooled data of 4 studies show that half of patients receiving antibiotics were not severe nor critical. Detailed data on antibiotic use lack in most articles.

Conclusions: The present review found a major use of antibiotics amongst Covid-19 hospitalized patients, mainly in an empirical setting. There is no proven efficacy of this practice. Further research to determine relevant indications for antibiotic use in Covid-19 patients is critical in view of the significant mortality associated with secondary infections in these patients, and the rising antimicrobial resistance.

Citing Articles

Long COVID and gut microbiome: insights into pathogenesis and therapeutics.

Lau R, Su Q, Ng S Gut Microbes. 2025; 17(1):2457495.

PMID: 39854158 PMC: 11776476. DOI: 10.1080/19490976.2025.2457495.


Screening novel antiviral compounds to treat Clostridioides difficile infections.

Stolz B, Abouelkhair A, Seleem M PLoS One. 2024; 19(12):e0309624.

PMID: 39671442 PMC: 11642915. DOI: 10.1371/journal.pone.0309624.


From Routine to Crisis: The Impact of COVID-19 Pandemic on Antibiotic Consumption in Iran.

Rezaei S, Bazyar M, Ahmadi S, Khodamoradi A Health Sci Rep. 2024; 7(11):e70161.

PMID: 39474349 PMC: 11519543. DOI: 10.1002/hsr2.70161.


Enhanced Treatment in Severe-Critical COVID-19 With Tocilizumab, Remdesivir, Dexamethasone: A Jordanian Cohort Study.

Al-Mistarehi A, El-Akawi S, Kheirallah K, Bani Ata E, Zaitoun K, Khassawneh A Cureus. 2024; 16(8):e67467.

PMID: 39314607 PMC: 11417280. DOI: 10.7759/cureus.67467.


Clinical Characteristics and Risk Factors of Mechanical Ventilation Among COVID-19 Patients on High-Flow Nasal Oxygen (HFNO).

Elrakaiby G, Ghabashi A, Sakhakhni A, Allaf F, Alamoudi S, Khan M Cureus. 2024; 16(7):e65462.

PMID: 39184683 PMC: 11345115. DOI: 10.7759/cureus.65462.